Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 106

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 106
---

See accompanying notes to consolidated financial statements

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-7

PACIRA BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022

(In thousands) Number of shares outstandingAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome (Loss)Total Common SharesTreasury SharesCommon StockTreasury StockBalance at December 31, 202144,734 — $45 $— $942,091 $(211,895)$167 $730,408 Reclassification of the equity component of convertible senior notes to liabilities upon adoption of Accounting Standards Update 2020-06— — — — (96,468)47,235 — (49,233)Exercise of stock options690 — 1 — 24,386 — — 24,387 Vested restricted stock units331 — — — — — — — Common stock issued under employee stock purchase plan71 — — — 2,954 — — 2,954 Stock-based compensation— — — — 48,092 — — 48,092 Issuance of common stock upon conversion of 2022 convertible senior notes102 — — — 3,040 — — 3,040 Other comprehensive loss (Note 12)— — — — — — (547)(547)Net income— — — — — 15,909 — 15,909 Balance at December 31, 202245,928 — 46 — 924,095 (148,751)(380)775,010 Exercise of stock options63 — — — 1,939 — — 1,939 Vested restricted stock units404 — — — (1)— — (1)Common stock withheld for employee withholding tax liabilities on vested restricted stock units(4)— — — (106)— — (106)Common stock issued under employee stock purchase plan90 — — — 2